New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.
The prognosis of advanced colorectal cancer remains poor in spite of the advances obtained in recent years with new therapeutic agents, new approaches in surgical procedures and new diagnostic methods. New treatments directed to molecular targets have emerged and are being developed to improve these results, but there is a need to optimize and define the best use of these new approaches. In this review, the authors examine the most important trials with monoclonal antibodies and tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
Capdevila
Jaume
J
Vall d'Hebron University Hospital, Medical Oncology Department, Barcelona, Spain. jacapdevila@vhebron.net
Mendez
Guillermo
G
Macarulla
Teresa
T
Ramos
Francisco Javier
FJ
Casado
Esther
E
Tabernero
Josep
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000628:therapy*; D006801:Humans
D000970:Antineoplastic Agents